Bone destruction in MM is supported by malignant plasma cells that favor OCL differentiation, including from DCs, through high RANK-L, IL-17 and TNFα production (Mansour et al., 2017; Noonan et al., 2010; Tucci et al., 2011). Here, IL17A is linked to Miyoshi myopathy.